Detection and quantitation of tetanus antitoxin in blood donations.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 475915)

Published in J Clin Pathol on December 01, 1975


A Barr, B C Dow, W C Watson, E Hunter

Articles by these authors

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71

Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07

Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68

Policy alternatives for resource allocation. Lancet (1977) 4.52

A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43

Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20

Multiple spells of in-patient treatment in a calendar year. Br J Prev Soc Med (1965) 3.70

A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70

A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69

Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol (1999) 3.49

HCV confirmatory testing of blood donors. Lancet (1991) 3.29

Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28

Testing of blood donations for hepatitis C virus. Lancet (1994) 3.27

Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18

Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol (1995) 3.10

Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06

Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol (1994) 2.90

Viral hepatitis markers in blood donors and patients with a history of jaundice. Lancet (1980) 2.90

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88

Total screening of blood donations for Australia (hepatitis associated) antigen and its antibody. Br Med J (1972) 2.65

Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56

Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53

Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51

Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51

A cumulative review of studies on travellers, their experience of illness and the implications of these findings. J Infect (1990) 2.50

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol (2001) 2.38

Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38

Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol (1993) 2.36

Refraction of 1-year-old children after cycloplegia with 1% cyclopentolate: comparison with findings after atropinisation. Br J Ophthalmol (1979) 2.35

Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34

Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion (1993) 2.24

Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23

Health care abuse. CMAJ (1994) 2.22

An intensive care unit: two years' experience in a provincial hospital. Br Med J (1965) 2.17

Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07

Lymphocytes in Whipple's disease. Lancet (1968) 2.06

Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med (1985) 2.01

Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99

Aortoenteric fistula. Incidence, presentation recognition, and management. Ann Surg (1982) 1.97

Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89

Hepatitis B antigen (HBAg) and its antibody (HBAb) in hospital patients. J Clin Pathol (1974) 1.88

Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85

Changes in refraction between the ages of 1 and 3 1/2 years. Br J Ophthalmol (1979) 1.85

Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83

A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83

Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81

A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80

Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80

Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68

The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67

Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care (2001) 1.67

Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67

Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54

Prevalence and epidemiological characteristics of hepatitis C in Scottish blood donors. Transfus Med (1994) 1.51

A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50

Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50

Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47

Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46

Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46

Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing. Vox Sang (2005) 1.45

Blood-donors with history of jaundice. Lancet (1979) 1.45

AIDS biosafety. Science (1991) 1.44

Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43

Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42

Hypertonicity of the cricopharyngeal sphincter: A cause of globus sensation. Lancet (1974) 1.41

The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly. EMBO J (1997) 1.38

Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38

Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38

Selection of plasma for hepatitis B immune globulin using a low cost radioimmunoassay. Vox Sang (1981) 1.38

Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38

Globus and headache: common symptoms of the irritable bowel syndrome. Can Med Assoc J (1978) 1.35

Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35

V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35

Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33

An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33

Total screening of blood donations for H.A.A. and anti-H.A.A. Lancet (1971) 1.33

Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31

Intestinal disaccharidase activity in rosacea. Br Med J (1966) 1.28

Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22

Characterization of "early" temperature-sensitive mutants of avian sarcoma viruses: biological properties, thermolability of reverse transcriptase in vitro, and synthesis of viral DNA in infected cells. Virology (1976) 1.22

Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21

Further studies on the inheritance of factor 8. Br J Haematol (1966) 1.21

Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21

Molecular cloning of the wild-type phoM operon in Escherichia coli K-12. J Bacteriol (1988) 1.20

A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19

Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol (1992) 1.19

Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18

Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retroviruses. J Biol Chem (1980) 1.17

Molecular events in the assembly of retrovirus particles. Adv Exp Med Biol (1998) 1.16

T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15

Neuroradiological and electroencephalographic features in a case of temporal lobe status epilepticus. Neurosurgery (1986) 1.15

Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14

Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57Bl/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum (1987) 1.14

Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13

Can otolith elemental chemistry retrospectively track migrations in fully marine fishes? J Fish Biol (2012) 1.12